BioMarin Pharmaceutical (BMRN) announced that the company received $20M in milestone payments from Pfizer (PFE). These milestone payments were triggered by the U.S. FDA acceptance of Pfizer’s New Drug Application submission for talazoparib and by the European Medicines Agency acceptance of Pfizer’s submission of a Marketing Authorization Application for talazoparib. These milestone payments are part of an agreement made with Medivation when the company purchased talazoparib. Medivation was acquired by Pfizer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.